Todd Engel runs his hand along the dining room table, pushed against a wall to help guide him through his Maryland home. On a good day, he can distinguish a shadow from the darkness.
Engel, 63, is legally blind. He can no longer drive and had to leave the job he loved operating heavy equipment. Most days, he stays home.
Four months after Engel started taking Ozempic to treat his diabetes, he woke one morning unable to see out of his right eye. His ophthalmologist told him the damage was permanent but couldn’t explain what caused it. No one suggested Ozempic might be involved, so Engel kept taking the GLP-1 drug.
Months later, he lost vision in his other eye.
“If anyone had told me there’s a possibility that this could happen there is just no way that I would ever take that medication,” Engel said.
Engel is now among thousands of patients suing Novo Nordisk and Eli Lilly, alleging they were not adequately warned about the risks of their blockbuster GLP-1 drugs.
For millions of patients, GLP-1 drugs have been safe and effective, delivering important health benefits for those struggling with obesity, diabetes, heart disease and more. But with many millions of people taking the drugs, some uncommon problems are coming to light.
Most cases appear to involve severe gastrointestinal injuries, but the list of potential complications under scrutiny is growing.
Whether Ozempic caused Engel’s blindness remains disputed. And the companies have maintained their products are safe.
“We recognize that vision loss can have a profound impact on patients and their families,” Novo Nordisk spokesperson Liz Skrbkova said in a statement. “Patient safety is a top priority for Novo, and we take all reports of adverse events seriously.”
Skrbkova said that semaglutide, the GLP-1 used in Novo Nordisk medications Ozempic and Wegovy, has a “well-established safety profile” and that the lawsuits filed against Novo Nordisk are “without merit.”
Eli Lilly said in a statement that it monitors, evaluates and reports safety information for all of its medicines to the Food and Drug Administration. “As part of our routine safety review process, we have ongoing discussions with regulators regarding potential safety topics, and we will continue to review data, including any data regarding ophthalmic or [gastrointestinal] issues.”
But as the lawsuits move through the courts, they are putting a difficult question at the center of the GLP-1 revolution: When millions of people are taking relatively new drugs, how much evidence of a rare but devastating risk is enough to require a warning?
Here’s what the latest research tells us about the potential risks of GLP-1 drugs — and what remains unknown.
Gastrointestinal and digestive
Novo’s Ozempic and Wegovy contain semaglutide, synthetic versions of the GLP-1s our bodies naturally make that regulate blood sugar and signal fullness. Lilly’s Mounjaro and Zepbound contain tirzepatide, which targets GLP-1 and GIP, another hormonal pathway involved in digestion. An even newer generation of drugs, including pills and medicines targeting three hormone pathways at once, is emerging.
Gastrointestinal effects were among the earliest and most common serious complications reported when the drugs first surged in popularity. As better data have accumulated, some of the scariest early signals have strengthened, while others have weakened.
The FDA labels, depending on the specific brand, already contain a substantial list of possible side effects but most are minor and temporary: nausea, diarrhea, belching, gas, constipation, abdominal pain and indigestion. But the drugs’ powerful effects on digestion and gut motility have also raised concerns about a smaller number of serious complications.
The big ones include:
Digestive tract problems — Gastroparesis, in which the stomach empties abnormally slowly, has been linked to GLP-1 drugs and an August review identified 13 published cases, most involving semaglutide, but researchers said larger studies are needed to determine how often it occurs and whether the drugs are responsible. Bowel obstruction also raised early alarms, but a large analysis found no increased risk overall.
Gallbladder and pancreatic problems — Gallstones are one of the clearer risks, with a review of 55 trials involving 106,395 people and finding a 46 percent increase, although the absolute risk was small. Pancreatitis remains on U.S. warning labels, but trials have not established a clear increased risk.
Reproductive
A lot of the early attention on GLP-1s and their possible effect on the reproductive system surrounded “Ozempic babies.” A number of women reported that they got pregnant after taking the drugs, but several studies have tried to understand whether the phenomenon has a biological basis impacting fertility or whether people were simply feeling healthier and having more sex.
Menstrual changes — Reports of unexpected bleeding and changes in menstrual cycles have followed the rise of GLP-1 drugs. A July study in the journal Obstetrics & Gynecology analyzing FDA adverse-event reports found disproportionate reports of heavy or between-period bleeding, menstrual clots, infrequent periods, and cycles without ovulation among semaglutide users. Tirzepatide showed signals for some bleeding problems, as well. For women with polyendocrine metabolic ovarian syndrome, or PMOS, a condition that can cause irregular periods, excess androgen levels and fertility problems, however, another July study, of 96 women, found that after six months of semaglutide, more than half of the participants who had not been ovulating began to ovulate.
Sex drive — A January paper in the journal Sexual Medicine Reviews found mixed human evidence: some patients report decreased libido, erectile dysfunction and difficulty with orgasm, while others report improved sexual desire or function. But researchers said the cause is unclear. It could be the drugs or it could be from weight loss, better health or improved body image.
Nutritional and physical
Doctors have repeatedly expressed concerns about whether some GLP-1 users are getting enough essential nutrients, particularly those who lose weight rapidly or eat substantially less. Some researchers warn that the most vulnerable patients could be at risk of malnutrition.
Nutritional deficiencies — A 2025 review of studies examining the issue found six papers that described GLP-1 users reporting nutritional deficiencies, including the lack of vitamin D, iron and calcium. A July study published by researchers at the University of Pennsylvania found that among 12,000 adults with Type 2 diabetes, taking GLP-1 drugs was associated with an increased risk of hair loss compared to other diabetes medication, although it stated the risk remains low. (Zepbound’s label lists hair loss as a possibility.)
Osteoporosis and fragility fractures — A preliminary study presented at an orthopedic meeting linked GLP-1 use to a higher risk of osteoporosis, while a separate study this year of more than 46,000 older adults with diabetes found those who took GLP-1s had an 11 percent higher risk of fragility fractures compared to those on other diabetes medication.
John Gabriel Horneff, an associate professor of clinical orthopedic surgery at the University of Pennsylvania and an author of the study on osteoporosis, said researchers aren’t sure why the two are connected but suggested that some patients might not be getting enough nutrition after starting GLP-1s.
“Patients think about this as a weight-loss drug, but you don’t just impact fat tissue,” Horneff said. “You impact muscle mass and certainly bone … as well.”
Cancer
For both semaglutide and tirzepatide, the boxes contain a prominent warning about thyroid C-cell tumors. The warning stems from studies in rats and mice in which the drugs caused these tumors.
So far, the human data has been more reassuring. An analysis in Annals of Internal Medicine in December 2025 of 48 placebo-controlled randomized trials involving 94,245 people found that GLP-1 drugs probably have little or no effect on the risk of thyroid, pancreatic, breast or kidney cancer.
In fact, some scientists believe that GLP-1s could help cancer patients. A few observational studies have suggested lower rates of obesity-related cancers, but it’s too soon to know whether the drugs are protective. Clinical trials are also underway to look at whether GLP-1s can slow down cancer growth.
Psychiatric and behavioral
Online, GLP-1 users describe such reactions as anhedonia, a strange sense that life has gone “meh”; anxiety; irritability; and dramatic shifts in mood. But the science on mental health and behavioral effects remains thin.
Anxiety or depression — Mental health and other medical experts say there isn’t enough data on how GLP-1s affect eating disorders and conditions such as anxiety or depression, although some have recommended caution. A study published in The Lancet Psychiatry in April followed about 95,500 people with diabetes or obesity who also had depression or anxiety. Those taking semaglutide had a lower risk of worsening depression and anxiety, substance-use disorder and self-harm. But the study was observational, meaning it could show an association, not that semaglutide caused the lower risk.
Eating disorders — GLP-1s have helped some patients interrupt disordered-eating patterns, while other patients have seen eating disorders return after taking weight-loss drugs, said Elizabeth Wassenaar, a regional medical director at Eating Recovery Center and Pathlight Mood & Anxiety Center.
“There’s a lot of unknowns,” Wassenaar said.
The European Medicines Agency said in 2023 that it was reviewing data on the risk of self-harm and suicidal thoughts for individuals taking GLP-1s. Wassenaar said she has also heard reports of patients whose moods worsened after taking GLP-1s, but she stressed that this evidence is also anecdotal. She recommended that patients taking GLP-1s discuss their mental health and any history of eating disorders with their prescribers.
“We just need to really make sure that we’re providing good mental health screening and mental health support for people that are being prescribed these medications,” she said.
Eyes
There is no evidence of a broad eye-safety problem with the use of GLP-1s, a counterpoint to the rare but serious issues like Engel’s. A 2026 study involving 5.5 million people found use of the drugs was associated with a lower incidence of macular degeneration. While the lack of evidence can’t prove the drugs are protective, it adds another layer of complexity to how people should think about them.
Diabetic retinopathy — An early semaglutide trial raised concerns that retinopathy (in which diabetes can damage tiny blood vessels in the retina, potentially causing bleeding, swelling and vision loss) could worsen in some patients. But a 2025 JAMA Ophthalmology review of 78 trials found no overall increased risk of diabetic retinopathy. This is listed as a risk on semaglutide labels.
NAION — Often called an “eye stroke,” nonarteritic anterior ischemic optic neuropathy occurs when blood flow to the optic nerve is disrupted, causing sudden loss of vision. The same JAMA ophthalmology paper found that semaglutide users had higher odds of NAION, although the researchers cautioned that cases were so rare they didn’t have the numbers for a definitive conclusion. But a newer study in March of 102,361 U.S. veterans was more alarming, finding that semaglutide users had roughly twice the NAION risk of patients starting a different common diabetes drug.
An April study of over 90,000 participants in clinical trials for Novo Nordisk’s GLP-1 products found no association between the drugs and NAION, said Skrbkova, the Novo Nordisk spokesperson.
Last week, after more than a year of studying the issue, the FDA ordered GLP-1 makers to included new safety labeling warning of a potentially higher risk of NAION. European regulators concluded last year that the evidence was sufficient to establish a causal relationship between semaglutide and NAION, classifying it as a “very rare” effect and directing patients to stop taking the drug if the condition is confirmed. Canada, Britain, Australia previously added warnings of their own.
Jonathan Orent of Motley Rice, Engel’s attorney and co-lead counsel in the NAION-related litigation, said the FDA’s delay left patients without critical information.
“This is not just a side effect, right? This is a life-altering catastrophe,” he said.
On Wednesday, he called the FDA warning “an important step forward for patient safety.”
Meanwhile, Engel’s days are now organized around counting steps, listening for landmarks and relying on others to take him places he once drove to himself. At his 13-year-old grandson’s bar mitzvah, he sat in the front row, less than 15 feet away. Tears ran down his face — he could hear but not see his grandson.
“I wake up in the dark,” he said, “and I go to sleep in the dark.”
The post The GLP-1 boom has a dark side — even if serious complications are rare appeared first on Washington Post.




